AI and life sciences – unpacking FDA regulatory issues

Wednesday, February 26, 2025 

Following the presidential transition, FDA has been engaged in a flood of activity, with more on the horizon.

The intersection of artificial intelligence (AI) and life sciences is heavily influenced by FDA regulatory considerations, and further change is anticipated to continually impact biotech, biologics, life sciences, and medical device companies.

Vernessa Pollard, Chair of DLA Piper’s FDA Regulatory practice, and Danny Tobey, Global Co-Chair and Chair of the firm’s Americas AI and Data Analytics practice, hosted a webinar to unpack the Administration’s regulatory changes and potential impacts to companies.

For more information
Please contact Ryan King with questions.

CLE credit was offered for this event.